Delivery Technologies for Protein Therapeutics: Assessment and Outlook
Tom Hollon, Ph.D
CHI INSIGHT PHARMA REPORTS – PROTEIN DRUG DELIVERY SURVEY – DECEMBER 2006
A survey of individuals in the pharmaceutical and biotech industries, and government and academic labs, who are involved with protein drug delivery R&D or commercialization.
Questions
Please classify your organization.
Please describe your organization’s primary involvement with therapeutic protein delivery technologies.
Can protein delivery technologies give your proteins new indications?
Can protein delivery technologies keep your proteins competitive in the marketplace?
Over the next 5 years, do you expect PEGylation to remain the most widely used and successful technology for protein half-life extension?
Are you currently increasing half-lives of your therapeutic proteins?
Are competitors developing longer half-life versions of your proteins?
What protein delivery method(s) are you developing as an alternative to injections?
Are competitors developing noninjection delivery vehicles for your proteins?
How will noninjection delivery vehicles affect patient compliance with drug therapy?
How will prices per course of treatment of improved delivery therapeutic protein products change in comparison to the original proteins?
Are you improving delivery for new protein therapeutics not yet approved by regulators, or only for proteins already approved?
Could oral protein delivery technologies threaten markets for transdermal protein delivery?
…….. pulmonary delivery?
…….. nasal protein delivery?
Will oral delivery alternatives to injectable proteins change the treating physician in some indications from specialist to primary care physician?
Today the trend to engineer proteins for longer half-life is mostly separate from the trend for noninjection delivery. Will delivering proteins engineered for longer half-life with noninjection technologies (transdermal, oral, pulmonary, nasal) be a major trend within 5 years?
Is your organization interested in noninjection delivery vehicles for monoclonal antibodies?
What are the greatest challenges confronting noninjection alternatives for MAb delivery?